Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: updated data from the long-term, multicenter, multinational, prospective, noninterventional BERING(MELANOMA) study

E Richtig; C Loquai; A Forschner; R Gutzmer; JC Hassel; JS Utikal; S Haferkamp; F Meier; Dirk Debus; R Dummer; RAF Von Moos; J Thompson; L Gengenbacher; O Michie-Lin; C Hoeller; D Schadendorf

Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: updated data from the long-term, multicenter, multinational, prospective, noninterventional BERING(MELANOMA) study

E Richtig, C Loquai, A Forschner, R Gutzmer, JC Hassel, JS Utikal, S Haferkamp, F Meier, Dirk Debus, R Dummer, RAF Von Moos, J Thompson, L Gengenbacher, O Michie-Lin, C Hoeller, D Schadendorf

Department of Dermatology

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	German
Pages (from-to)	96-97
Journal	JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
Volume	20
Publication status	Published - 2022

Cite this

Richtig, E., Loquai, C., Forschner, A., Gutzmer, R., Hassel, JC., Utikal, JS., Haferkamp, S., Meier, F., Debus, D., Dummer, R., Von Moos, RAF., Thompson, J., Gengenbacher, L., Michie-Lin, O., Hoeller, C., & Schadendorf, D. (2022). Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: updated data from the long-term, multicenter, multinational, prospective, noninterventional BERING(MELANOMA) study. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 20, 96-97.

@article{31679bb7669e420da157d30c602410f9,

title = "Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: updated data from the long-term, multicenter, multinational, prospective, noninterventional BERING(MELANOMA) study",

author = "E Richtig and C Loquai and A Forschner and R Gutzmer and JC Hassel and JS Utikal and S Haferkamp and F Meier and Dirk Debus and R Dummer and {Von Moos}, RAF and J Thompson and L Gengenbacher and O Michie-Lin and C Hoeller and D Schadendorf",

year = "2022",

language = "Deutsch",

volume = "20",

pages = "96--97",

journal = "JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT",

issn = "1610-0379",

publisher = "Wiley Verlag ",

}

Richtig, E, Loquai, C, Forschner, A, Gutzmer, R, Hassel, JC, Utikal, JS, Haferkamp, S, Meier, F, Debus, D, Dummer, R, Von Moos, RAF, Thompson, J, Gengenbacher, L, Michie-Lin, O, Hoeller, C & Schadendorf, D 2022, 'Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: updated data from the long-term, multicenter, multinational, prospective, noninterventional BERING(MELANOMA) study', JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, vol. 20, pp. 96-97.

Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: updated data from the long-term, multicenter, multinational, prospective, noninterventional BERING(MELANOMA) study. / Richtig, E; Loquai, C; Forschner, A et al.
In: JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 20, 2022, p. 96-97.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: updated data from the long-term, multicenter, multinational, prospective, noninterventional BERING(MELANOMA) study

AU - Richtig, E

AU - Loquai, C

AU - Forschner, A

AU - Gutzmer, R

AU - Hassel, JC

AU - Utikal, JS

AU - Haferkamp, S

AU - Meier, F

AU - Debus, Dirk

AU - Dummer, R

AU - Von Moos, RAF

AU - Thompson, J

AU - Gengenbacher, L

AU - Michie-Lin, O

AU - Hoeller, C

AU - Schadendorf, D

PY - 2022

Y1 - 2022

M3 - Abstrakt (Zeitschrift)

SN - 1610-0379

VL - 20

SP - 96

EP - 97

JO - JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

JF - JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

ER -

Richtig E, Loquai C, Forschner A, Gutzmer R, Hassel JC, Utikal JS et al. Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: updated data from the long-term, multicenter, multinational, prospective, noninterventional BERING(MELANOMA) study. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. 2022;20:96-97.